Premium
CDK4/6 inhibitor plus endocrine therapy for hormone receptor‐positive, HER2‐negative metastatic breast cancer: The new standard of care
Author(s) -
Hui Rina,
Boer Richard,
Lim Elgene,
Yeo Belinda,
Lynch Jodi
Publication year - 2021
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13555
Subject(s) - metastatic breast cancer , medicine , oncology , breast cancer , cancer , endocrine system , aromatase inhibitor , clinical trial , hormone , tamoxifen
Patients presenting with hormone receptor‐positive (HR + ), human epidermal growth factor receptor 2‐negative (HER2 – ) metastatic breast cancer (MBC) are usually treated with endocrine therapy (ET), except if there is a concern about endocrine resistance or a need to achieve rapid disease control due to visceral crisis. The combination of CDK4/6 inhibitor + ET has now replaced single‐agent ET as the standard first‐line treatment; and it can also be considered a standard option in the second‐line setting. This review briefly summarizes recently reported efficacy findings from the key phase III clinical trials of CDK4/6 inhibitor + ET in patients with HR + /HER2 – MBC, including evidence that adding a CDK4/6 inhibitor to ET improves overall survival and does so without reducing patients’ quality of life. There is still much to learn regarding the use of CDK4/6 inhibitors and how they may be optimally integrated into clinical practice. In particular, there is a need for specific biomarkers that help predict the likelihood of response or resistance to CDK4/6 inhibitor therapy; and for data to guide treatment decisions when a patient's disease progresses on a CDK4/6 inhibitor.